SecBot SecBot
PRESS-RELEASE ·Filed Jul 30, 2026

PVLA

Palvella Therapeutics Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed3mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

This filing is a routine press release with no material trading implications. Monitor the upcoming August 5 FDA meeting for any policy signals, but no immediate catalyst for PVLA shares.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$150.19
T+0 close · Jul 30, 2026 · via day close
Latest settled
−16.71%
T+60 · $125.10
Vs SPY
−19.17%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 30 $150.19entry
  2. T+1 · 4mo ago −7.42%α −8.13% · $139.04
  3. T+5 · 3mo ago +3.16%α −0.47% · $154.93
  4. T+20 · 3mo ago +0.09%α −3.87% · $150.33
  5. T+60 · 25d ago −16.71%α −19.17% · $125.10
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Palvella Therapeutics announced that its Chief Scientific Officer, Dr. Jeffrey Martini, has been selected to provide public comment at an FDA public meeting on drug repurposing on August 5, 2026. This is a routine speaking engagement with no financial or regulatory impact on the company's pipeline or stock.

Key Facts

  • Dr. Martini will provide public comment at an FDA public meeting on drug repurposing on August 5, 2026.
  • The meeting is convened by the Reagan-Udall Foundation in collaboration with the FDA.
  • No financial data, clinical results, or regulatory decisions were announced.

Financial Impact

None, no financial metrics disclosed or impacted.

Risk Factors

  • No material risks identified in the filing.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3335947

Track record

36 reports on PVLA

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +35.07% at T+60 after the May 15, 2026 report. 8 of 10 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $145.21 Now $144.60 −0.42% settles Dec 16
  2. Nov 10, 20266d ago 144 Neutral 5/10 Entry $163.94 Now $144.60 −11.80% settles Dec 10
  3. Nov 5, 202611d ago 8-K Bullish 7/10 Entry $156.85 Now $144.60 −7.81% settles Dec 4
  4. Nov 5, 202611d ago Press Release Neutral 6/10 No price data
  5. Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $152.93 Now $144.60 −5.45% settles Dec 2
  6. Oct 28, 202619d ago SC 13G/A Neutral 3/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
  7. Oct 28, 202619d ago 8-K Bullish 6/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
  8. Oct 28, 202619d ago Press Release Bullish 7/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
  9. Oct 23, 202624d ago Insider Cluster Neutral 2/10 Entry $126.23 Now $144.60 +14.55% settles Nov 23
  10. Oct 15, 20264w ago Press Release Neutral 4/10 Entry $127.34 to $153.18 Now $144.60 +13.55% ▲ +20.29% +22.19% vs SPY
Showing 10 of 36

US Market Status

Market Closed · Opens in 6h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 30, 2026